In univariate analyses, IGHV mutation status, TP53 disruption, and the presence of a BTK or PLCG2 mutation status were not predictors of shorter OS from time of CLL disease progression on ibrutinib. Here, PLCG2 is linked to B-cell chronic lymphocytic leukemia.